254 related articles for article (PubMed ID: 24804240)
1. mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.
Wang Z; Jin W; Jin H; Wang X
Biomed Res Int; 2014; 2014():735672. PubMed ID: 24804240
[TBL] [Abstract][Full Text] [Related]
2. Phenformin-Induced Mitochondrial Dysfunction Sensitizes Hepatocellular Carcinoma for Dual Inhibition of mTOR.
Veiga SR; Ge X; Mercer CA; Hernández-Álvarez MI; Thomas HE; Hernandez-Losa J; Ramón Y Cajal S; Zorzano A; Thomas G; Kozma SC
Clin Cancer Res; 2018 Aug; 24(15):3767-3780. PubMed ID: 29691292
[No Abstract] [Full Text] [Related]
3. Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells.
Zhen MC; Wang FQ; Wu SF; Zhao YL; Liu PG; Yin ZY
Oncotarget; 2017 Feb; 8(6):9466-9475. PubMed ID: 28036295
[TBL] [Abstract][Full Text] [Related]
4. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
5. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M
Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739
[TBL] [Abstract][Full Text] [Related]
6. Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma.
Ferrín G; Guerrero M; Amado V; Rodríguez-Perálvarez M; De la Mata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32070029
[TBL] [Abstract][Full Text] [Related]
7. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
8. Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.
Lu X; Paliogiannis P; Calvisi DF; Chen X
Hepatology; 2021 Jan; 73 Suppl 1(Suppl 1):49-61. PubMed ID: 32394479
[TBL] [Abstract][Full Text] [Related]
9. The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415.
Zhang W; Chen B; Zhang Y; Li K; Hao K; Jiang L; Wang Y; Mou X; Xu X; Wang Z
Biochem Biophys Res Commun; 2017 Jun; 487(3):494-499. PubMed ID: 28366631
[TBL] [Abstract][Full Text] [Related]
10. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.
Chen Y; Zhang L; Yang C; Han J; Wang C; Zheng C; Zhou Y; Lv J; Song Y; Zhu J
Bioorg Med Chem; 2016 Mar; 24(5):957-66. PubMed ID: 26819001
[TBL] [Abstract][Full Text] [Related]
11. Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice.
Lang SA; Moser C; Fichnter-Feigl S; Schachtschneider P; Hellerbrand C; Schmitz V; Schlitt HJ; Geissler EK; Stoeltzing O
Hepatology; 2009 Feb; 49(2):523-32. PubMed ID: 19085954
[TBL] [Abstract][Full Text] [Related]
12. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends.
Matter MS; Decaens T; Andersen JB; Thorgeirsson SS
J Hepatol; 2014 Apr; 60(4):855-65. PubMed ID: 24308993
[TBL] [Abstract][Full Text] [Related]
13. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Zhou Q; Lui VW; Yeo W
Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
[TBL] [Abstract][Full Text] [Related]
14. PI3K/AKT/mTOR pathway-related long non-coding RNAs: roles and mechanisms in hepatocellular carcinoma.
Wu Y; Zhang Y; Qin X; Geng H; Zuo D; Zhao Q
Pharmacol Res; 2020 Oct; 160():105195. PubMed ID: 32916254
[TBL] [Abstract][Full Text] [Related]
15. The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth.
Wang C; Wang X; Su Z; Fei H; Liu X; Pan Q
Oncol Rep; 2015 Oct; 34(4):1708-16. PubMed ID: 26239364
[TBL] [Abstract][Full Text] [Related]
16. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.
Thomas HE; Mercer CA; Carnevalli LS; Park J; Andersen JB; Conner EA; Tanaka K; Matsutani T; Iwanami A; Aronow BJ; Manway L; Maira SM; Thorgeirsson SS; Mischel PS; Thomas G; Kozma SC
Sci Transl Med; 2012 Jun; 4(139):139ra84. PubMed ID: 22539746
[TBL] [Abstract][Full Text] [Related]
17. mTor as a potential target for the prevention and treatment of hepatocellular carcinoma.
Buitrago-Molina LE; Vogel A
Curr Cancer Drug Targets; 2012 Nov; 12(9):1045-61. PubMed ID: 22873368
[TBL] [Abstract][Full Text] [Related]
18. Gene and protein expression of mTOR and LC3 in hepatocellular carcinoma, colorectal liver metastasis and "normal" liver tissues.
Bortolami M; Comparato A; Benna C; Errico A; Maretto I; Pucciarelli S; Cillo U; Farinati F
PLoS One; 2020; 15(12):e0244356. PubMed ID: 33362215
[TBL] [Abstract][Full Text] [Related]
19. mTOR inhibitor for the treatment of hepatocellular carcinoma.
Kudo M
Dig Dis; 2011; 29(3):310-5. PubMed ID: 21829022
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
